Search results
Results From The WOW.Com Content Network
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [ 7][ 8]
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency ...
(Reuters) -The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and 59, making it the first shot ...
July 3, 2024 at 4:14 AM. (Reuters) -British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA ...
AS03 (for "Adjuvant System 03") is the trade name for a squalene -based immunologic adjuvant used in various vaccine products by GlaxoSmithKline (GSK). It is used, for example, in GSK's A/H1N1 pandemic flu vaccine Pandemrix. It is also in Arepanrix and the Q-pan for H5N1 influenza. [1] A dose of AS03 adjuvant contains [2] In the 2009 influenza ...
One issue in developing the vaccine is the need for bark extract from the tree Quillaja saponaria that is used in combination with monophosphoryl lipid A as an immunologic adjuvant. This adjuvant is used by several other GSK vaccines—especially the shingles vaccine that is more profitable—and GSK owns most of the world's supply.